RA
CTMX icon

Royce & Associates’s CytomX Therapeutics CTMX Stock Holding History

Royce & Associates’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-499
Closed -$11K – 1186
2018
Q2 		$11K Buy
499
+274
+122% +$7K ﹤0.01% 1193
2018
Q1 		$6K Sell
225
-141
-39% -$4.02K ﹤0.01% 1233
2017
Q4 		$8K Sell
366
-75
-17% -$1.55K ﹤0.01% 1207
2017
Q3 		$8K Buy
+441
New +$6.88K ﹤0.01% 1188

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Royce & Associates's CTMX Position: Q3 2018 in Review

Royce & Associates sold out of CytomX Therapeutics (CTMX) in Q3 2018, closing a stake of 499 shares — an estimated $11K sold.

Royce & Associates first reported a position in CTMX in Q3 2017 and held it in 4 quarters. The position peaked at $11K in Q2 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q3 2018.

  • Royce & Associates reported no remaining CytomX Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Royce & Associates sold 499 CytomX Therapeutics shares in Q3 2018, an estimated $11K.
  • Royce & Associates first reported a position in CytomX Therapeutics in Q3 2017 and held it in 4 quarters.
  • Royce & Associates's CytomX Therapeutics position peaked at $11K in Q2 2018.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2018.

Based on Royce & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.